NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Sutcliffe P, Connock M, Gurung T, et al. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews. Southampton (UK): NIHR Journals Library; 2013 Sep. (Health Technology Assessment, No. 17.43.)

Cover of Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews

Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.

Show details

References

1.
National Institute for Health and Care Excellence (NICE). Statins for the prevention of cardiovascular events. London: NICE; 2008.
2.
British Heart Foundation. Coronary heart disease statistics. 2012. URL: www​.bhf.org.uk/publications​/view-publication.aspx?ps=1002097. Accessed on 1 November 2012.
3.
Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, Minhas R, Sheikh A, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475–82. 10.1136/bmj.39609.449676.25. [PMC free article: PMC2440904] [PubMed: 18573856] [CrossRef]
4.
NHS Clinical Knowledge Summaries. Cardiovascular risk assessment and management – management. 2012. URL: http://cks​.nice.org.uk​/cvd-risk-assessment-and-management. Accessed on 9 September 2012.
5.
Diabetes UK. Diabetes in the UK 2012. Key statistics on diabetes. 2012. URL: www​.diabetes.org.uk/Documents​/Reports/Diabetes-in-the-UK-2012.pdf. Accessed on 8 November 2012.
6.
Eckel RH, Kahn R, Robertson RM, Rizza RA. Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association. Circulation 2006;113:2943–6. 10.1161/CIRCULATIONAHA.106.176583. [PubMed: 16801475] [CrossRef]
7.
Schnell O, Erbach M, Hummel M. Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. Diab Vasc Dis Res 2012;9:245–55. 10.1177/1479164112441486. [PubMed: 22508698] [CrossRef]
8.
Cancer Research UK. CancerStats (Incidence 2009-UK). http://publications​.cancerresearchuk​.org​/cancerstats/statsincidence/incidence​.html. 1 May 2012. Accessed on 1 October 2012.
9.
Scottish Intercollegiate Guidelines Network (SIGN). Risk estimation and the prevention of cardiovascular disease (a national clinical guideline). 2007. URL: www​.sign.ac.uk/pdf/sign97.pdf. Accessed on 1 August 2012.
10.
JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl. 5):v1–52. [PMC free article: PMC1876394] [PubMed: 16365341]
11.
National Institute for Health and Care Excellence (NICE). National Collaborating Centre for Primary Care (NCCPC). Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Clinical guideline 67. London: NICE; 2010. [PubMed: 21834195]
12.
Luengo-Fernandez R, Leal J, Gray A, Petersen S, Rayner M. Cost of cardiovascular diseases in the United Kingdom. Heart 2006;92:1384–9. 10.1136/hrt.2005.072173. [PMC free article: PMC1861058] [PubMed: 16702172] [CrossRef]
13.
Featherstone H and Witham L. The cost of cancer. 2010. URL: http://www.policyexchange.org.uk/images/publications/the cost of cancer - feb 10.pdf. Accessed on 1 November 2012.
14.
Kanavos P, Aardweg S van den, and Schurer W. Diabetes expenditure, burden of disease and management in 5 EU countries. LSE Health, London School of Economics. http://www2​.lse.ac.uk​/LSEHealthAndSocialCare​/research/LSEHealth​/MTRG/LSEDiabetesReport26Jan2012.pdf. Accessed on 1 November 2012.
15.
National Institute for Health and Care Excellence (NICE). Type 2 diabetes. The management of type 2 diabetes. NICE clinical guideline 66, 2008. Accessed on 1 October 2012.
16.
Goldstein LB, Bushnell CCD, Adams RJ, Appel LJ, Braun LT, Chaturvedi S, et al. Guidelines for the Primary Prevention of Stroke A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association. Stroke 2011;42:517–84. 10.1161/STR.0b013e3181fcb238. [PubMed: 21127304] [CrossRef]
17.
Ringleb PA, Bousser MG, Ford G, Bath P, Brainin M, Caso V, et al. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. The European Stroke Organization (ESO) Executive Committee and the ESO Writing Committee. Cerebrovasc Dis 2008;25:457–507. [PubMed: 18477843]
18.
Aspirin for the prevention of cardiovascular disease: US Preventive Services Task Force recommendation statement. Ann Intern Med 2009;150:396–404. [PubMed: 19293072]
19.
Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007;14(Suppl. 2):1–113. 10.1097/01.hjr.0000277983.23934.c9. [PubMed: 17726407] [CrossRef]
20.
Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al. Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes A Position Statement of the American Diabetes Association, a Scientific Statement of the American Heart Association, and an Expert Consensus Document of the American College of Cardiology Foundation. Circulation 2010;121:2694–701. 10.1161/CIR.0b013e3181e3b133. [PubMed: 20508178] [CrossRef]
21.
Perk J, de BG, Gohlke H, Graham I, Reiner Z, Verschuren WM, et al. European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by Representatives of Nine Societies and by Invited Experts). Int J Behav Med 2012;19:403–88. [PubMed: 23093473]
22.
Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31–41. 10.1016/S0140-6736(10)62110-1. [PubMed: 21144578] [CrossRef]
23.
Department of Health (DoH). Improving outcomes: a strategy for cancer. London: DoH; 2011.
24.
US Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer. Ann Intern Med 2007;146:361–4. [PubMed: 17339621]
25.
Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest 1975;56:624–32. 10.1172/JCI108132. [PMC free article: PMC301910] [PubMed: 1159076] [CrossRef]
26.
DeWitt DL, el-Harith EA, Kraemer SA, Andrews MJ, Yao EF, Armstrong RL, et al. The aspirin and heme-binding sites of ovine and murine prostaglandin endoperoxide synthases. J Biol Chem 1990;265:5192–8. [PubMed: 2108169]
27.
Schachter M. Aspirin in CVD prevention. BJCPN 2005;2:202–3.
28.
Burch JW, Stanford N, Majerus PW. Inhibition of platelet prostaglandin synthetase by oral aspirin. J Clin Invest 1978;61:314–19. 10.1172/JCI108941. [PMC free article: PMC372541] [PubMed: 413839] [CrossRef]
29.
Awtry EH, Loscalzo J. Aspirin. Circulation 2000;101:1206–18. 10.1161/01.CIR.101.10.1206. [PubMed: 10715270] [CrossRef]
30.
Din FVN, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut 2010;59:1670–9. 10.1136/gut.2009.203000. [PubMed: 20844293] [CrossRef]
31.
Rothwell PM, Wilson M, Elwin CE, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010;376:1741–50. 10.1016/S0140-6736(10)61543-7. [PubMed: 20970847] [CrossRef]
32.
Dovizio M, Bruno A, Tacconelli S, Patrignani P. Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 2013;191:39–65. 10.1007/978-3-642-30331-9_3. [PubMed: 22893199] [CrossRef]
33.
Xie WL, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA 1991;88:2692–6. 10.1073/pnas.88.7.2692. [PMC free article: PMC51304] [PubMed: 1849272] [CrossRef]
34.
Negrotto S, Malaver E, Alvarez ME, Pacienza N, D’Atri LP, Pozner RG, et al. Aspirin and salicylate suppress polymorphonuclear apoptosis delay mediated by proinflammatory stimuli. J Pharmacol Exp Ther 2006;319:972–9. 10.1124/jpet.106.109389. [PubMed: 16936242] [CrossRef]
35.
Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255–8. 10.1016/S0049-3848(03)00379-7. [PubMed: 14592543] [CrossRef]
36.
Hirata Y, Kataoka H, Shimura T, Mizushima T, Mizoshita T, Tanida S, et al. Incidence of gastrointestinal bleeding in patients with cardiovascular disease: buffered aspirin versus enteric-coated aspirin. Scand J Gastroenterol 2011;46:803–9. 10.3109/00365521.2011.568522. [PubMed: 21501103] [CrossRef]
37.
Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011;107:1796–801. 10.1016/j.amjcard.2011.02.325. [PubMed: 21481826] [CrossRef]
38.
Raju N, Sobieraj-Teague M, Hirsh J, O’Donnell M, Eikelboom J. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011;124:621–9. 10.1016/j.amjmed.2011.01.018. [PubMed: 21592450] [CrossRef]
39.
Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 2011;162:115–24. 10.1016/j.ahj.2011.04.006. [PubMed: 21742097] [CrossRef]
40.
Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840. 10.1136/bmj.a1840. [PMC free article: PMC2658865] [PubMed: 18927173] [CrossRef]
41.
de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357:89–95. [PubMed: 11197445]
42.
Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, Pell AC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841–8. 10.1001/jama.2010.221. [PubMed: 20197530] [CrossRef]
43.
Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755–62. 10.1016/S0140-6736(98)04311-6. [PubMed: 9635947] [CrossRef]
44.
Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. [Erratum published in JAMA 2009;301:1882.]. JAMA 2008;300:2134–41. 10.1001/jama.2008.623. [PubMed: 18997198] [CrossRef]
45.
Peto R, Gray R, Collins R, Wheatley K, Hennekens C, Jamrozik K, et al. Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J 1988;296:313–16. 10.1136/bmj.296.6618.313. [PMC free article: PMC2544821] [PubMed: 3125882] [CrossRef]
46.
Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352:1293–304. 10.1056/NEJMoa050613. [PubMed: 15753114] [CrossRef]
47.
Final report on the aspirin component of the ongoing Physicians’ Health Study. Steering Committee of the Physicians’ Health Study Research Group. N Engl J Med 1989;321:129–35. [PubMed: 2664509]
48.
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council’s General Practice Research Framework. Lancet 1998;351:233–41. [PubMed: 9457092]
49.
Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602–12. 10.1016/S0140-6736(11)61720-0. [PubMed: 22440946] [CrossRef]
50.
NHS Centre for Reviews and Dissemination (CRD). Undertaking systematic reviews of research on effectiveness: CRD guidelines for those carrying out or commissioning reviews. CRD Report 4. York: NHS Centre for Reviews and Dissemination, University of York; 1999.
51.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reveiws of Interventions, version 5.1.0. 2011, March. URL: www​.cochrane-handbook.org/. Accessed on 1 October 2012.
52.
Adelman EE, Lisabeth L, Brown DL. Gender differences in the primary prevention of stroke with aspirin. Women Health 2011;7:341–52. 10.2217/whe.11.21. [PubMed: 21612354] [CrossRef]
53.
Antithrombotic Trialists’: A, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849–60. [PMC free article: PMC2715005] [PubMed: 19482214]
54.
Raju NC, Eikelboom JW. The aspirin controversy in primary prevention. Curr Opin Cardiol 2012;27:499–507. 10.1097/HCO.0b013e328356ae95. [PubMed: 22874127] [CrossRef]
55.
Selak V, Elley CR, Wells S, Rodgers A, Sharpe N. Aspirin for primary prevention: yes or no? J Primary Health Care 2010;2:92–9. [PubMed: 20690297]
56.
Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Int Med 2012;172:209–16. 10.1001/archinternmed.2011.628. [PubMed: 22231610] [CrossRef]
57.
Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. An Int Med 2009;150:405–10. 10.7326/0003-4819-150-6-200903170-00009. [PubMed: 19293073] [CrossRef]
58.
Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, et al. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Australia 2008;189:105–9. [PubMed: 18637782]
59.
Dorresteijn JA, Visseren FL, Ridker PM, Paynter NP, Wassink AM, Buring JE, et al. Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects. Eur Heart J 2011;32:2962–9. 10.1093/eurheartj/ehr423. [PMC free article: PMC3227855] [PubMed: 22090661] [CrossRef]
60.
Mills EJ, Wu P, Alberton M, Kanters S, Lanas A, Lester R. Low-dose aspirin and cancer mortality: a meta-analysis of randomized trials. Am J Med 2012;125:560–7. 10.1016/j.amjmed.2012.01.017. [PubMed: 22513195] [CrossRef]
61.
Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518–27. 10.1016/S1470-2045(12)70112-2. [PubMed: 22440112] [CrossRef]
62.
Rothwell PM, Wilson M, Price JF, Belch JF, Meade TW, Mehta Z. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012;379:1591–601. 10.1016/S0140-6736(12)60209-8. [PubMed: 22440947] [CrossRef]
63.
Butalia S, Leung AA, Ghali WA, Rabi DM. Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 2011;10:25. 10.1186/1475-2840-10-25. [PMC free article: PMC3098148] [PubMed: 21453547] [CrossRef]
64.
Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, Geske JB, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009;32:2300–6. 10.2337/dc09-1297. [PMC free article: PMC2782995] [PubMed: 19741185] [CrossRef]
65.
De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531. 10.1136/bmj.b4531. [PMC free article: PMC2774388] [PubMed: 19897665] [CrossRef]
66.
Simpson SH, Gamble JM, Mereu L, Chambers T. Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Int Med 2011;26:1336–44. 10.1007/s11606-011-1757-y. [PMC free article: PMC3208465] [PubMed: 21647746] [CrossRef]
67.
Stavrakis S, Stoner JA, Azar M, Wayangankar S, Thadani U. Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci 2011;341:1–9. 10.1097/MAJ.0b013e3181f1fba8. [PubMed: 21191260] [CrossRef]
68.
Younis N, Williams S, Ammori B, Soran H. Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother 2010;11:1459–66. 10.1517/14656561003792538. [PubMed: 20429671] [CrossRef]
69.
Zhang C, Sun A, Zhang P, Wu C, Zhang S, Fu M, et al. Aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2010;87:211–18. 10.1016/j.diabres.2009.09.029. [PubMed: 19853947] [CrossRef]
70.
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306–13. 10.1001/jama.295.3.306. [PubMed: 16418466] [CrossRef]
71.
Cleland JG. Systematic reporting bias in meta-analyses of trials of aspirin for the primary prevention of cardiovascular disease. Am J Med 2012;125:e13. 10.1016/j.amjmed.2011.08.027. [PubMed: 22269629] [CrossRef]
72.
Wells S, Broad J, Jackson R. Estimated prevalence of cardiovascular disease and distribution of cardiovascular risk in New Zealanders: data for healthcare planners, funders, and providers. N Z Med J 2006;119:1935–43. [PubMed: 16633394]
73.
Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group. Lancet 1991;338:1345–9. [PubMed: 1682734]
74.
Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991;54:1044–54. 10.1136/jnnp.54.12.1044. [PMC free article: PMC1014676] [PubMed: 1783914] [CrossRef]
75.
Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 1992;268:1292–300. [PubMed: 1507375]
76.
Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. The Swedish Angina Pectoris Aspirin Trial (SAPAT) Group. Lancet 1992;340:1421–5. [PubMed: 1360557]
77.
European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255–62. [PubMed: 7901582]
78.
European Stroke Prevention Study 2 Group. European stroke prevention study: 2. Efficacy and safety data. J Neurol Sci 1997;151(Suppl.):S1–77. [PubMed: 9276859]
79.
Higgins J, Green S. Cochrane handbook for systematic reviews of interventions. Chichester: The Cochrane Collaboration and John Wiley and Sons Ltd; 2008.
80.
Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials – correction. JAMA 2006;295:2002. doi:10​.1001/jama.295.17.2002. [PubMed: 16418466]
81.
Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Low-dose aspirin in the primary prevention of cancer: the Women’s Health Study: a randomized controlled trial. JAMA 2005;294:47–55. 10.1001/jama.294.1.47. [PubMed: 15998890] [CrossRef]
82.
Sturmer T, Glynn RJ, Lee IM, Manson JE, Buring JE, Hennekens CH. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians’ Health Study. Ann Intern Med 1998;128:713–20. 10.7326/0003-4819-128-9-199805010-00003. [PubMed: 9556464] [CrossRef]
83.
Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, Fortmann SP, et al. AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 2002;106:388–91. 10.1161/01.CIR.0000020190.45892.75. [PubMed: 12119259] [CrossRef]
84.
Burn J, Gerdes AM, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2012;378:2081–7. 10.1016/S0140-6736(11)61049-0. [PMC free article: PMC3243929] [PubMed: 22036019] [CrossRef]
85.
Ridker PM, Cook NR, Buring JE. Use of aspirin as primary prevention of cardiovascular events. JAMA 2006;296:391–2. 10.1001/jama.296.4.391-a. [PubMed: 16868289] [CrossRef]
Copyright © Queen's Printer and Controller of HMSO 2013. This work was produced by Sutcliffe et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Included under terms of UK Non-commercial Government License.

Bookshelf ID: NBK261082

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (5.4M)

Other titles in this collection

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...